Alnylam Pharmaceuticals (NASDAQ:ALNY) is scheduled to be releasing its earnings data after the market closes on Tuesday, February 6th.
Shares of Alnylam Pharmaceuticals (ALNY) opened at $124.50 on Friday. The firm has a market capitalization of $12,726.96, a PE ratio of -23.71 and a beta of 2.69. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. Alnylam Pharmaceuticals has a 12-month low of $39.66 and a 12-month high of $147.63.
ALNY has been the topic of a number of analyst reports. Morgan Stanley raised their target price on Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the company an “equal weight” rating in a research report on Thursday, November 9th. Cowen restated a “buy” rating and set a $151.00 target price on shares of Alnylam Pharmaceuticals in a research report on Thursday, November 9th. Credit Suisse Group raised their target price on Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an “outperform” rating in a research report on Friday, November 3rd. Leerink Swann raised their target price on Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the company a “market perform” rating in a research report on Thursday, January 25th. Finally, Needham & Company LLC restated a “buy” rating and set a $152.00 target price (up from $125.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $123.93.
In related news, CEO John Maraganore sold 74,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total value of $9,387,640.00. Following the transaction, the chief executive officer now directly owns 223,710 shares of the company’s stock, valued at approximately $28,379,850.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Michael Mason sold 36,745 shares of the firm’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the transaction, the vice president now directly owns 6,352 shares in the company, valued at $835,859.68. The disclosure for this sale can be found here. Insiders sold a total of 220,409 shares of company stock worth $28,667,017 over the last ninety days. 4.30% of the stock is currently owned by corporate insiders.
WARNING: “Alnylam Pharmaceuticals (ALNY) to Release Earnings on Tuesday” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/02/04/alnylam-pharmaceuticals-alny-to-release-earnings-on-tuesday.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.